Galcanezumab Cuts Migraine Days: Real-World Study Insights
- MigraineMind
- Nov 18, 2025
- 1 min read
Research Summary
A recent study published in Headache systematically reviewed and analyzed the real-world effectiveness and safety of galcanezumab for migraine treatment. The research pooled data from 36 studies, focusing on reducing monthly migraine days (MMDs), monthly headache days (MHDs), and assessing the Headache Impact Test scores. Results showed a significant decrease in MMDs by almost 7 days and MHDs by over 8 days one month after the first injection. More than 60% of patients experienced at least a 50% reduction in these metrics within three months. While the treatment showed promising safety outcomes, with constipation being the most common side effect, the evidence certainty remains limited by study heterogeneity.
Study Details
👥 Research Team: Fernández-Bravo-Rodrigo J et al.
📚 Published In: Headache
📅 Publication Date: 2025 Nov 17
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.